TREATMENT WITH HUMAN MONOCLONAL ANTIBODY TO CONNECTIVE TISSUE GROWTH FACTOR (FG-

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 FG-3019治疗将提供2个月的治疗，并将在整个2个月的治疗期间进行稳态PK。该药将每两周给药一次，共4剂。FG-3019将以静脉输注的方式进行2小时以上的注射。患者在输液后将在医院停留6个小时进行观察。在2个月的治疗期内，患者将总共6次就诊。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. FG-3019 treatment will be provided for 2 months and steady state PK will be conducted throughout the 2 month treatment period. The drug will be administered every 2 weeks for a total of 4 doses. FG-3019 will be administered as an intravenous infusion over 2 hours. The patient will remain in the hospital for 6 hours following the infusion for observation .The patient will be seen for a total of 6 visits over the 2 month treatment period.